Dyne Therapeutics Inc
Research Dyne Therapeutics Inc (DYN) on Bullrun: market cap USD 4.36B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDYN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.36B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 178.56M
- Free cash flow-USD 131.80M
Valuation Snapshot
latest market cap is USD 4.36B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 446 | -USD 405.13M | n/a | -3.47 | USD 893.37M | USD 148.92M | USD 972.13M |
| FY2024 | USD 0 | -USD 317 | -USD 294.75M | n/a | -3.37 | USD 435.45M | USD 0 | USD 629.84M |
| FY2023 | n/a | -USD 236 | -USD 188.89M | n/a | -3.95 | USD 121.63M | USD 27.42M | USD 91.29M |
| FY2022 | n/a | -USD 168 | -USD 156.71M | n/a | -3.23 | USD 172.15M | USD 32.83M | USD 252.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.36B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.23B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.41B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 816.40M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 604.15M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 613.16M | n/a | n/a | n/a |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dyne Therapeutics Inc's market cap?
Dyne Therapeutics Inc's market capitalization is USD 4.36B.
What does Dyne Therapeutics Inc do?
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc.